All In MedTech

FDA Clearance Tracker · P110033-S099

SKINVIVE by JUVEDERM®

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 11, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 11, 2026

Approved

Time to decision

394 days

Received May 13, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P110033-S099
Device name
SKINVIVE by JUVEDERM®
Applicant
Allergan
Applicant location
Irvine, CA
Received
May 13, 2025
Decided
Jun 11, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P110033

Device type

Device class
Class III

Every decision under product code LMH

FDA's approval statement

As written in FDA's record.

SKINVIVE by JUVÉDERM® is indicated for intradermal injection to improve skin smoothness of the cheeks and intradermal and/or subdermal injection to reduce neck lines for improvement of neck appearance in adults over the age of 21

Source documents

Other decisions for Allergan

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.